A SMART Design for Attendance-based Prize CM

Not Applicable

Completed

• Conditions: Substance Abuse
• Interventions: Behavioral: contingency management

• Registration Number: NCT00840151
• Lead Sponsor: UConn Health

Brief Summary

The purpose of this study is to compare different forms of treatment for substance abuse. This study will involve a type of treatment called contingency management, in which patients receive incentives (prizes) for attending outpatient treatment. This study will compare contingency management to standard treatment that does not involve incentives. This study will also compare contingency management treatment that lasts 6 weeks to contingency management that lasts 12 weeks. Finally, this study will compare contingency management treatment delivered at the beginning of outpatient treatment to contingency management treatment delivered later during outpatient treatment. The investigators hypothesize that (1) a 12-week attendance-based contingency management intervention will improve retention and enhance drug abstinence versus standard treatment, (2) initial short-term exposure to attendance-based contingency management (in weeks 1-6 only) will improve substance abuse treatment outcomes compared to standard treatment alone, and (3) contingency management in weeks 7-12 will be particularly useful for those with sporadic attendance or continued drug use during initial stages of treatment.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-01
• Study First Submitted: 2009-02-07
• Study First Submitted QC: 2009-02-09
• Study First Posted: 2009-02-10
• Primary Completion: 2014-08
• Study Completion: 2014-08
• Status Verified: 2019-04
• Last Update Submitted: 2019-04-05
• Last Update Posted: 2019-04-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 360

Inclusion Criteria

• age > 18 years
• current DSM-IV diagnosis of cocaine abuse or dependence or recent cocaine use (self-reported use in past 30 days or positive urine toxicology screen)
• willing to sign informed consent and able to pass an informed consent quiz

Exclusion Criteria

• serious, uncontrolled psychiatric illness (e.g., acute schizophrenia, bipolar disorder, severe or psychotic major depression, or suicide risk) on the basis of history or medical examination
• in recovery from pathological gambling (meet DSM-IV criteria for lifetime pathological gambling and are actively trying to refrain from gambling)
• do not speak English (all treatment is provided in English at these clinics)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: FACTORIAL

Arm && Interventions

Group	Intervention	Description
Treatment Group B	contingency management	Individuals randomized to Treatment Group B will receive contingency management plus standard treatment for study weeks 1-6.
Aftercare Group B	contingency management	All participants will be re-randomized after study week 6. Those participants assigned to Aftercare Group B will receive contingency management treatment plus standard treatment for weeks 7-12.

Primary Outcome Measures

Name	Time	Method
longest duration of negative drug and alcohol samples submitted	throughout active phase and at each follow-up assessment

Secondary Outcome Measures

Name	Time	Method
proportions of samples testing negative for drugs and alcohol	during active phase and at each follow-up assessment
psychosocial functioning and HIV risk behaviors	baseline, active phase and at each follow-up assessment

Trial Locations

Locations (1)

University of Connecticut Health Center; 🇺🇸 Farmington, Connecticut, United States